Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
Fotini Vogiatzi(Christian-Albrechts-Universität zu Kiel), Dorothee Winterberg(Christian-Albrechts-Universität zu Kiel), Lennart Lenk(Christian-Albrechts-Universität zu Kiel), Swantje Buchmann(Christian-Albrechts-Universität zu Kiel), Gunnar Cario(Christian-Albrechts-Universität zu Kiel), Martin Schrappe(Christian-Albrechts-Universität zu Kiel), Matthias Peipp(Christian-Albrechts-Universität zu Kiel), Paulina Richter‐Pechańska(Heidelberg University), Andreas E. Kulozik(Heidelberg University), Jana Lentes, Anke Bergmann, Thomas Valerius(Christian-Albrechts-Universität zu Kiel), Fabian‐Simon Frielitz(University of Lübeck), Christian Kellner(Ludwig-Maximilians-Universität München), Denis M. Schewe(Christian-Albrechts-Universität zu Kiel)
Cited by 58Open Access
Abstract
TO THE EDITOR: Novel immunotherapies have recently led to a broadened spectrum of therapeutic options in pediatric B-cell precursor acute lymphoblastic leukemia, even in the setting of relapsed/refractory disease. However, antibody therapy for T-cell acute lymphoblastic leukemia (T-ALL) is
Related Papers
No related papers found
Powered by citation graph analysis